CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis

Shailesh P. Dudhgaonkar, Srihari B. Janardhanam, Krithika N. Kodumudi, Mythily Srinivasan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Designing mimetic of the interface functional groups of known receptor-ligand complexes is an attractive strategy for developing potential therapeutic agents that interfere with target protein-protein interactions. The CD80/CD86-CD28/CD152 costimulatory interactions transmit signals for CD4 + T cell activation and suppression and are critically involved in the initiation, progression, and reactivation of the immunopathology in multiple sclerosis. Differences in the pattern, levels, and kinetics of expression of CD80/CD86 molecules in conjunction with differences in the strength of the signals delivered upon binding CD28 or CD152 determine the outcome of the immune response. A temporal up-regulation of surface expression of CD80 relative to CD86 on APCs and CNS-infiltrating cells has been shown to correlate with disease progression in experimental autoimmune encephalomyelitis an animal model for multiple sclerosis. Hence blockade of the CD80 costimulatory axis has therapeutic potential in multiple sclerosis. In this study, we report the efficacy of a novel CD80-blocking agent CD80-competitive antagonist peptide (CD80-CAP) in suppressing clinical disease and relapse in experimental autoimmune encephalomyelitis. The CD80-CAP mediates protection by inhibiting proinflammatory cytokines and skewing toward anti-inflammatory response presumably by enhancing the expression of glucocorticoid-induced leucine zipper in activated CD4 + T cells.

Original languageEnglish (US)
Pages (from-to)7505-7513
Number of pages9
JournalJournal of Immunology
Volume183
Issue number11
DOIs
StatePublished - Dec 1 2009

Fingerprint

Leucine Zippers
Autoimmune Experimental Encephalomyelitis
Glucocorticoids
Multiple Sclerosis
T-Lymphocytes
Disease Progression
Proteins
Anti-Inflammatory Agents
Up-Regulation
Animal Models
Cytokines
Ligands
Recurrence
Therapeutics
CD80-CAP

ASJC Scopus subject areas

  • Immunology

Cite this

CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis. / Dudhgaonkar, Shailesh P.; Janardhanam, Srihari B.; Kodumudi, Krithika N.; Srinivasan, Mythily.

In: Journal of Immunology, Vol. 183, No. 11, 01.12.2009, p. 7505-7513.

Research output: Contribution to journalArticle

Dudhgaonkar, Shailesh P. ; Janardhanam, Srihari B. ; Kodumudi, Krithika N. ; Srinivasan, Mythily. / CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis. In: Journal of Immunology. 2009 ; Vol. 183, No. 11. pp. 7505-7513.
@article{6da812fdd4c7400abe577bdf19fe264f,
title = "CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis",
abstract = "Designing mimetic of the interface functional groups of known receptor-ligand complexes is an attractive strategy for developing potential therapeutic agents that interfere with target protein-protein interactions. The CD80/CD86-CD28/CD152 costimulatory interactions transmit signals for CD4 + T cell activation and suppression and are critically involved in the initiation, progression, and reactivation of the immunopathology in multiple sclerosis. Differences in the pattern, levels, and kinetics of expression of CD80/CD86 molecules in conjunction with differences in the strength of the signals delivered upon binding CD28 or CD152 determine the outcome of the immune response. A temporal up-regulation of surface expression of CD80 relative to CD86 on APCs and CNS-infiltrating cells has been shown to correlate with disease progression in experimental autoimmune encephalomyelitis an animal model for multiple sclerosis. Hence blockade of the CD80 costimulatory axis has therapeutic potential in multiple sclerosis. In this study, we report the efficacy of a novel CD80-blocking agent CD80-competitive antagonist peptide (CD80-CAP) in suppressing clinical disease and relapse in experimental autoimmune encephalomyelitis. The CD80-CAP mediates protection by inhibiting proinflammatory cytokines and skewing toward anti-inflammatory response presumably by enhancing the expression of glucocorticoid-induced leucine zipper in activated CD4 + T cells.",
author = "Dudhgaonkar, {Shailesh P.} and Janardhanam, {Srihari B.} and Kodumudi, {Krithika N.} and Mythily Srinivasan",
year = "2009",
month = "12",
day = "1",
doi = "10.4049/jimmunol.0902056",
language = "English (US)",
volume = "183",
pages = "7505--7513",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis

AU - Dudhgaonkar, Shailesh P.

AU - Janardhanam, Srihari B.

AU - Kodumudi, Krithika N.

AU - Srinivasan, Mythily

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Designing mimetic of the interface functional groups of known receptor-ligand complexes is an attractive strategy for developing potential therapeutic agents that interfere with target protein-protein interactions. The CD80/CD86-CD28/CD152 costimulatory interactions transmit signals for CD4 + T cell activation and suppression and are critically involved in the initiation, progression, and reactivation of the immunopathology in multiple sclerosis. Differences in the pattern, levels, and kinetics of expression of CD80/CD86 molecules in conjunction with differences in the strength of the signals delivered upon binding CD28 or CD152 determine the outcome of the immune response. A temporal up-regulation of surface expression of CD80 relative to CD86 on APCs and CNS-infiltrating cells has been shown to correlate with disease progression in experimental autoimmune encephalomyelitis an animal model for multiple sclerosis. Hence blockade of the CD80 costimulatory axis has therapeutic potential in multiple sclerosis. In this study, we report the efficacy of a novel CD80-blocking agent CD80-competitive antagonist peptide (CD80-CAP) in suppressing clinical disease and relapse in experimental autoimmune encephalomyelitis. The CD80-CAP mediates protection by inhibiting proinflammatory cytokines and skewing toward anti-inflammatory response presumably by enhancing the expression of glucocorticoid-induced leucine zipper in activated CD4 + T cells.

AB - Designing mimetic of the interface functional groups of known receptor-ligand complexes is an attractive strategy for developing potential therapeutic agents that interfere with target protein-protein interactions. The CD80/CD86-CD28/CD152 costimulatory interactions transmit signals for CD4 + T cell activation and suppression and are critically involved in the initiation, progression, and reactivation of the immunopathology in multiple sclerosis. Differences in the pattern, levels, and kinetics of expression of CD80/CD86 molecules in conjunction with differences in the strength of the signals delivered upon binding CD28 or CD152 determine the outcome of the immune response. A temporal up-regulation of surface expression of CD80 relative to CD86 on APCs and CNS-infiltrating cells has been shown to correlate with disease progression in experimental autoimmune encephalomyelitis an animal model for multiple sclerosis. Hence blockade of the CD80 costimulatory axis has therapeutic potential in multiple sclerosis. In this study, we report the efficacy of a novel CD80-blocking agent CD80-competitive antagonist peptide (CD80-CAP) in suppressing clinical disease and relapse in experimental autoimmune encephalomyelitis. The CD80-CAP mediates protection by inhibiting proinflammatory cytokines and skewing toward anti-inflammatory response presumably by enhancing the expression of glucocorticoid-induced leucine zipper in activated CD4 + T cells.

UR - http://www.scopus.com/inward/record.url?scp=73349142360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349142360&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0902056

DO - 10.4049/jimmunol.0902056

M3 - Article

C2 - 19917693

AN - SCOPUS:73349142360

VL - 183

SP - 7505

EP - 7513

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -